The Vision Council, independent optometric alliance groups, and eyewear manufacturers advocated on Capitol Hill last month for policies aimed at preserving affordable access to vision care. During meetings with lawmakers, industry leaders emphasized that tariffs on optical products are increasing costs for patients and placing a strain on independent eye care practices.
The coalition delivered a unified message that trade policy decisions directly affect patient access to prescription eyewear, which is essential to public health, education, and workforce productivity.
Vision Care = Health Care
With more than 70% of Americans relying on prescription eyewear, leaders warned that even modest cost increases may cause patients to delay care. Industry representatives stressed that this could cause role conditions such as diabetes-related eye disease and glaucoma to go undetected.
“We appreciated the opportunity to meet with lawmakers and share real-world examples of how current trade policies are driving up costs for both businesses and patients,” says Ashley Mills, CEO of The Vision Council. She notes that prescription eyewear does not receive the same tariff exemptions as other low-risk medical products, despite being classified as a Class I medical device.
Meetings With Congressional Offices
The group met with representatives from 11 Congressional offices, as well as staff from the Energy and Commerce Health Subcommittee, which oversees healthcare policy and programs that affect access to vision care. Discussions focused on how tariffs impact optical manufacturers, suppliers, retailers, and independent optometric practices.
Leaders also addressed challenges facing small and mid-sized companies seeking to expand domestic manufacturing. They expressed their support for strengthening U.S.-based production while citing barriers to growth such as limited access to raw materials such as acetate along with labor, regulatory costs, and ongoing tariffs.
The coalition urged lawmakers to consider tariff relief for low-risk optical medical devices and stronger coordination among federal agencies. Leaders also previewed ongoing advocacy efforts, including a bipartisan congressional letter and potential legislation focused on lowering prescription eyewear costs and preserving access to care.